ARVN

About Arvinas, Inc (ARVN) Stock

Arvinas, Inc (ARVN) closed the 2026-09-16 session at $8.15, down 1.27% versus the previous close (-0.11). The stock opened at $8.31 and traded between $8.12 and $8.32 during that session. Session trading volume was 288K shares. The volume-weighted average price (VWAP) is $8.19.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Arvinas, Inc has a market capitalization of $540.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ARVN is listed on the XNAS exchange. The company employs approximately 246 people. Arvinas, Inc is headquartered in NEW HAVEN, CT. The recorded listing date is 2018-09-27.

On this page you can find market ARVN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.